PubMed Health⌕ Search

Biomedical subjects

F H Johnson

Publications and source records attributed to F H Johnson.

At least 19 recordsLinked to original sources
PubMed1990

The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study.

The effects of gamma-hydroxybutyrate (GHB: 25 mg/kg h.s. and 3 h later) vs. placebo on objectively evaluated nighttime sleep and daytime sleepiness in narcolepsy were evaluated in a double-blind, counterbalanced crossover design. Twenty narcolepsy patients were given an overnight polysomnogram (PSG), followed by a daytime multiple sleep latency test (MSLT) at baseline and on the 1st and 29th days of GHB and placebo treatment. The overnight PSGs indicated that the narcolepsy patients had the following significant results during GHB versus placebo treatment: decreased stage 1 (p = 0.012), increased stage 3 (p = 0.008), increased delta (stage 3 and 4 combined) sleep (p = 0.049), fewer stage shifts (p = 0.002), and fewer awakenings (p = 0.006). Minutes of wakefulness were significantly increased only for the last 2 h of the 8 h sleep period on GHB versus placebo (p = 0.019), which is beyond the time of GHB's direct influence. The MSLTs indicated that the narcolepsy patients had a marginally increased sleep latency mean during GHB versus placebo treatment (p = 0.074) and significantly increased total stage 0 (wakefulness) on day 29 of GHB versus day 29 of placebo treatment (p = 0.038). Female narcolepsy patients had significantly fewer naps with REM sleep (REM naps) on day 29 of GHB vs. day 29 of placebo treatment (p = 0.020). The therapeutic effect of GHB in narcolepsy patients, i.e., decreases cataplexy, appears to be due to its improving nocturnal sleep quality, since its half-life is only 1.5 to 2 h. It is conjectured that GHB, an endogenous neurochemical, may be a sleep neurotransmitter or neuromodulator, since GHB rapidly induces sleep, and increases sleep continuity and delta sleep without suppressing REM sleep in both normals and narcolepsy patients.

Adult↗
PubMed1989

Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.

The efficacy of gamma-hydroxybutyrate (GHB) versus placebo for treating narcolepsy was evaluated in 20 patients with narcolepsy, 10 men and 10 women, using a double-blind counterbalanced crossover design. Each patient completed a daily sleep-wake log and questionnaire during a 14-day baseline, a 29-day placebo period, a 29-day GHB period (50 mg GHB/kg/night given 25 mg/kg h.s. and 25 mg/kg 3 hr later), and a 6-day washout period after each treatment. Cataplexy frequency was significantly lower during GHB treatment than during placebo treatment (p = 0.022). Compared to baseline values, the number of cataplexy attacks per day declined by 52% and 69% during GHB treatment weeks 1 and 4, respectively. The number of subjective arousals from sleep was less with GHB than with placebo (p = 0.035), and the number of sleep attacks was not significantly different during GHB versus placebo treatment. GHB did not have a significant effect on subjective estimates of sleep onset latency, total sleep time, Stanford Sleepiness Scale ratings at morning wake-up, methylphenidate usage, or the number of naps per day. The results indicate that GHB is efficacious for reducing the frequency of cataplexy attacks and subjective nocturnal arousals in patients with narcolepsy within the first 4 weeks of treatment.

Adolescent↗
PubMed1980

Efficiency of medium utilization by human diploid fibroblasts in culture.

Growth of two human diploid cell strains were studied in relation to medium formulation, supplementation and inoculum size. MRC-5 cells were found to give greatly improved yields in Dulbecco Modified Eagle's medium, while a foreskin strain, HFS-30, showed only a slight effect. Supplementation of nutrient by the addition of fresh medium after two days incubation and the use of small inocula, gave enhanced yields and medium utilisation in both cell types.

Cell Division↗
PubMed1978

Properties and reaction mechanism of the bioluminescence system of the deep-sea shrimp Oplophorus gracilorostris.

The bioluminescent reaction of Oplophorus takes place when the oxidation of coelenterazine (the luciferin) with molecular oxygen is catalyzed by Oplophorus luciferase, resulting in light of maximum intensity at 462 nm and the products CO2 and coelenteramide. Oplophorus luciferase has now been obtained in a highly purified state. Optimum luminescence occurs at pH 9 in the presence of 0.05--0.1 M NaCl at 40 degrees C, and, due to the unusual resistance of this enzyme to heat, visible luminescence occurs at temperatures above 70 degrees C when partially purified enzyme is used. The specific activity of purest preparations is 1.75 X 10(15) photons s-1 mg-1 at 23 degrees C. At pH 8.7, native luciferase has a molecular weight of approximately 130 000, apparently comprising 4 monomers of 31 000; at lower pHs, the native luciferase tends to polymerize. The quantum yield of coelenterazine is 0.34 at 22 degrees C with this enzyme. After the luminescent reaction, the spent solution is nonfluorescent, and likewise solutions of luciferase alone. When the bioluminescent reaction was carried out in the presence of 18O2, the product CO2 contained more than 50% C18O16O, supporting the dioxetane mechanism, but without ruling out the linear peroxide mechanism.

Animals↗
PubMed1978

Peroxidized coelenterazine, the active group in the photoprotein aequorin.

The photoprotein aequorin emits light by an intramolecular reaction when Ca2+ is added under either aerobic or anaerobic conditions. Previously reported evidence has indicated two possibilities: (i) the functional group of aequorin is coelenterazine itself, a compond that plays key roles in the bioluminescence of various other types of organisms, or (ii) it is the enolized form of this compound. Present data rule out both of these possibilities, through elucidation of the structure of the yellow compound that is split off aequorin by treatment with NaHSO3. The yellow compound is now shown to be a tertiary alcohol of coelenterazine on the basis of chemical reactions, mass spectral data, and relationships to known derivatives of coelenterazine. From this structure and the method of forming the yellow compound from aequorin, aequorin evidently contains a peroxide of coelenterazine as the active group. The presence of such a peroxide is consistent with the fact that aequorin yields free coelenterazine upon treatment with Na2S2O4. Although there is no applicable technique at present to determine with assurance the specific state of the peroxide in the protein, a study with 18O tracer indicates that a linear peroxide structure is more likely than the alternative possibility of a dioxetane structure.

Aequorin↗
PubMed1977

Source of oxygen in the CO(2) produced in the bioluminescent oxidation of firefly luciferin.

Incorporation of (18)O into the CO(2) produced in the bioluminescent oxidation of firefly luciferin was studied. In H(2) (16)O medium with (18)O(2) gas, the product CO(2) contained up to 75% C(16)O(18)O, showing that one O of the product CO(2) arose from the O(2) that oxidized luciferin. This result is consistent with a dioxetane mechanism. Analysis of the mass spectral data of the CO(2) obtained in high-enrichment H(2) (18)O medium with (16)O(2) gas indicated the presence of about 20% contaminating CO(2), which contributes approximately 70% of the total incorporated (18)O. Thus the values of incorporated (18)O in H(2) (18)O medium with (16)O(2) gas have no significance in the present context. Data obtained with luciferases of the American firefly Photinus and Japanese firefly Luciola were similar.

Journal Article↗
PubMed1975

Chemical nature of bioluminescence systems in coelenterates.

Analysis of substances involved in light-emitting reactions among bioluminescent coelenterates has revealed a pronounced uniformity in the structural features of initial reactants, i.e., "luciferins" and photo-protein chromophores, as well as the light-emitter product. This product is structurally identical among the different classes of coelenterates: Hydrozoa (the jellyfish, Aequorea), Anthozoa (the sea cactus, Cavernularia; sea pansy, Renilla; and sea pen, Leioptilus), and very likely also the Scyphozoa (the jellyfish, Pelagia). In each of these instances the reaction product, namely, 2-(p-hydroxy-pnenylacetyl)amino-3-benzyl-5-(p-hydroxyphenyl) pyrazine, is the actual light-emitter, whether it occurs in a Ca2+-triggered photoprotein type of luminescence, or in a "luciferin-luciferase" type. The evidence indicates that in certain coelenterates, e.g., Cavernularia, these two types are equally significant, whereas in others (Renilla and Leioptilus) the "luciferin-luciferase" type predominates over the Ca-triggerable photoprotein type, and finally that only the photoprotein type functions in the luciferaseless jellyfish, Aequorea. In all instances investigated, the structure of the light-emitter prior to the luminescence reaction appears to be essentially the same as that of the chromophore of unreacted aequorin. The product of the luminescence reaction is absent in extracts of non luminous species. However, a product very similar to that of luminescent coelenterates occurs also in representatives of other phyla, including the cephalopod molluscs, e.g., the "firefly squid" Watasenia and probably various ctenophores as well.

Animals↗
PubMed1974

The aldehyde content of luminous bacteria and of an "aldehydeless" dark mutant.

Fatty aldehydes, present in the luminescent cells of Photobacterium phosphoreum and Achromobacter fischeri, and to a very slight extent in the cells of a visually dark, "aldehydeless" mutant of the latter species, were extracted, purified, and oxidized to the corresponding acids. The acids were analyzed by mass spectrometry. The results, in conjunction with various other lines of evidence, indicate that saturated fatty aldehydes, comprising mostly dodecanal, tetradecanal, and hexadecanal, function in the bioluminescent reaction in living cells of these luminous bacteria. The amount of these aldehydes in the cells was computed to be sufficient to sustain steady-state luminescence for a period of about 1 sec, and under such conditions the rate of oxidation of the aldehydes in the process of luminescence must be balanced by their rate of production.

Alcaligenes↗